Bepridil hydrochloride for treatment of benign or potentially lethal ventricular arrhythmias |
| |
| Authors: | P F Nestico J Morganroth L N Horowitz C Mulhern |
| |
| Affiliation: | 1. Department of Clinical Psychology, Friedrich-Schiller-Universität, Jena, Germany;2. Institute for Psychology, Universität der Bundeswehr München, Munich, Germany;3. Faculty of Philosophy and Munich Centre for Neuroscience, Ludwig Maximilian University, Munich, Germany;4. Research Centre Brain & Behavior, Liverpool John Moores University, UK;1. Cardiac Arrhythmia Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;2. Cardiac Rhythm and Heart Failure Division, Medtronic plc, Minneapolis, Minnesota;3. Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina;1. Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia, USA;2. Virginia Commonwealth University/Pauley Heart Center, Richmond, Virginia, USA;3. Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA;4. Washington Veterans Affairs Medical Center, Washington, DC, USA;1. Department of Radiation Oncology, University of Toronto, Toronto, Canada;2. Radiation Medicine Program, Princess Margaret Cancer Center, Toronto, Canada;3. Division of Radiation Oncology, University of British Columbia and BC Cancer, Victoria, BC, Canada |
| |
| Abstract: | To define the efficacy and safety of a new once-a-day calcium antagonist, bepridil, 21 patients with frequent ventricular premature complexes (VPCs) underwent a 14-day inpatient monitored trial. After Holter monitoring during placebo administration, patients underwent 2 days of a loading dose of bepridil followed by 12 days of bepridil, 400 mg/day. Holter monitoring during therapy showed that 10 patients (48%) had more than a 70% reduction in VPC frequency and 8 of 16 patients (50%) at least a 95% reduction in frequency of nonsustained ventricular tachycardia. Gastrointestinal and central nervous system side effects considered to be mild occurred in 13 patients (62%). One patient had an asymptomatic increase in VPC frequency and another had sustained ventricular tachycardia associated with a loading dose of 900 mg of bepridil. Thus, bepridil has moderate antiarrhythmic efficacy in patients with ventricular arrhythmias, but further definition of its potential for causing proarrhythmia must be determined. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
